Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Belite Bio, Inc. ADR ( (BLTE) ).
On March 17, 2025, Belite Bio, Inc announced the availability of its annual report on Form 20-F for the year ended December 31, 2024, on its website. This announcement, made in compliance with Nasdaq Listing Rule 5250(d)(1)(C), provides shareholders with access to the company’s audited consolidated financial statements, potentially impacting stakeholder transparency and investor relations.
More about Belite Bio, Inc. ADR
Belite Bio is a clinical-stage biopharmaceutical company based in San Diego, focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 and Geographic Atrophy in advanced dry age-related macular degeneration, as well as specific metabolic diseases. Its lead candidate, Tinlarebant, is under evaluation in multiple clinical trials.
YTD Price Performance: 4.15%
Average Trading Volume: 44,650
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.08B
For detailed information about BLTE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue